COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Pentoxifylline with a dose of 400 mg, made by Farabi Pharmaceutical Company, Iran, was prescribed to patients weighing less than 70 kg every 12 hours and to patient
Sponsors
Karaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: Clinical signs of fever (above 38.3 °C), dyspnea and cough Definite diagnosis of of Covid-19 based on RT-PCR
Exclusion criteria
Exclusion criteria: Diabetes Chronic cardiovascular disease Obesity (with BMI higher than 30 kg/m2) Cancer Chronic kidney disease End-stage renal disease with hemodialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oxygen saturation of arterial blood. Timepoint: Before intervention, daily after intervention. Method of measurement: Pulse-oximeter monitoring. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: 7, 14, 21 and 28 days after intervention. Method of measurement: Clinical examination by physician and confirmation of death.;Refer to the intensive care unit. Timepoint: 7, 14, 21 and 28 days after intervention. Method of measurement: Clinical Frailty Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSajjad Pourasghary
Oroumia University of Medical Sciences
Outcome results
None listed